The In-Vitro Diagnostic Substance Manufacturing Industry in the US has displayed fluctuating growth over the past decade, with actual values reaching $18.41 billion in 2023. Historical data highlights significant annual variations, notably with growth spurts in certain intervals such as a notable rise from 2015 to 2016 (8.46%) and a more modest but stable increase from 2019 to 2022 ranging from 1.75% to 1.97% year-on-year. The industry has shown resilience, culminating in a 2023 value marking a 1.69% growth over the previous year.
Forecasts indicate a gradual upward trend with a Compound Annual Growth Rate (CAGR) of 1.19% over the next five years, demonstrating cautious optimism regarding industry expansion. By 2028, the gross output is anticipated to escalate to $19.85 billion, translating to an overall growth of 6.09% from 2023.
Future trends to watch for include:
- Technological advancements in diagnostic methods and automation.
- Increasing demand for personalized medicine and point-of-care diagnostics.
- Regulatory changes impacting market entry and product approvals.
- Expansion in emerging markets contributing to global industry growth.
